23 July 2025
23 July 2025
The UK is the first country to introduce a dedicated law to manufacture medicines at the point of care.
The new facility will manufacture peptides, small molecules and oligonucleotides.
Vicebio's product pipeline features VXB-241, a bivalent vaccine that targets RSV and hMPV.
Sarepta CEO Doug Ingram said it is important the company maintains a “positive working relationship” with the FDA.
Icotrokinra is currently being developed through a licensing and collaboration agreement between Protagonist and J&J.
The new investment will support the ongoing development of Biogen's late-stage clinical pipeline.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
